BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline May 3, 2024
AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B May 3, 2024
XyloCor Therapeutics Positive EXACT Phase 2 Data for Lead Candidate XC001 Simultaneously Presented at Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions and Published in Circulation: Cardiovascular Interventions May 3, 2024
Carbon Biosciences Announces Four Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting May 3, 2024
Tome Biosciences to Present Data on Programmable Genomic Integration Technologies at ASGCT April 24, 2024
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting April 24, 2024
